QNTM
Get informed when a big investor buys or sells
+ FollowOvervalued by 99.7% based on the discounted cash flow analysis.
| Market cap | $20.48 Million |
|---|---|
| Enterprise Value | $17.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.11 |
| Beta | 0.45 |
| Outstanding Shares | 6,651,217 |
| P/E Ratio | -0.57 |
|---|---|
| PEG | 0.86 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.46 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.12 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 6.24%▲ 0.58% |
|---|---|
| Total Invested | $1.50M▲ 22.49% |
| Investors Holding | 27▲ 3.00% |
No data
fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based...